Long-acting GnRH-agonist depotForesee Pharmaceuticals

FP-001 (leuprolide mesylate)

FP-001 is a long-acting leuprolide mesylate depot formulated for six-month dosing intervals. Foresee is developing the 42 mg dose to suppress gonadotropins in children with central precocious puberty while reducing injection frequency.

Also known as: FP-001, leuprolide mesylate, LMIS

Forecast a trial in the ArenaBrowse all benchmarks
1
Trials tracked
1
Resolved
1
Indications
1
Targets

FP-001 (leuprolide mesylate) forecasting benchmarks

1 benchmark
ResolvedPhase 3

Casppian Phase 3: FP-001 leuprolide mesylate 42 mg q6mo Central Precocious Puberty (CPP)

FP-001 (leuprolide mesylate) · Central precocious puberty

Dec 24, 2025Clinical Trials

Mechanism & molecular targets

GnRH-R· gene

Indications studied

Central precocious puberty· CPP

Developed by

Foresee Pharmaceuticals· FSEE

About FP-001 (leuprolide mesylate)

What is FP-001 (leuprolide mesylate)?

FP-001 is a long-acting leuprolide mesylate depot formulated for six-month dosing intervals. Foresee is developing the 42 mg dose to suppress gonadotropins in children with central precocious puberty while reducing injection frequency. It is a long-acting gnrh-agonist depot developed by Foresee Pharmaceuticals.

What does FP-001 (leuprolide mesylate) target?

FP-001 (leuprolide mesylate) acts on GnRH receptor (GNRHR).

How well do AI models predict FP-001 (leuprolide mesylate) trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.

Keep exploring

All benchmarksDiseasesCompaniesTargets & genes